{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:41:20Z","timestamp":1790908880264,"version":"4.1.0"},"reference-count":30,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2016,2,2]]},"DOI":"10.3233\/jad-150818","type":"journal-article","created":{"date-parts":[[2016,2,8]],"date-time":"2016-02-08T07:28:13Z","timestamp":1454916493000},"page":"733-740","source":"Crossref","is-referenced-by-count":46,"title":["Serotonin 2A Receptor Inverse Agonist as a Treatment for Parkinson\u2019s Disease Psychosis: A Systematic Review and Meta-analysis of Serotonin 2A Receptor Negative Modulators"],"prefix":"10.1177","volume":"50","author":[{"given":"Ichiro","family":"Yasue","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"},{"name":"Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Okehazama Hospital, Toyoake, Aichi, Japan"},{"name":"The Neuroscience Research Center, Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-150818_ref1","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/bmb\/ldn013","article-title":"A review of Parkinson\u2019s disease","volume":"86","author":"Davie","year":"2008","journal-title":"Br Med Bull"},{"key":"10.3233\/JAD-150818_ref2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"de Lau","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.3233\/JAD-150818_ref3","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/aje\/kwg068","article-title":"Incidence of Parkinson\u2019s disease: Variation by age, gender, and race\/ethnicity","volume":"157","author":"Van Den Eeden","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.3233\/JAD-150818_ref4","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/mds.25945","article-title":"The prevalence of Parkinson\u2019s disease: A systematic review and meta-analysis","volume":"29","author":"Pringsheim","year":"2014","journal-title":"Mov Disord"},{"key":"10.3233\/JAD-150818_ref5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/089198870201500307","article-title":"Atypical antipsychotics in Parkinson-sensitive populations","volume":"15","author":"Friedman","year":"2002","journal-title":"J Geriatr PsychiatryNeurol"},{"key":"10.3233\/JAD-150818_ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-015-1400-x"},{"issue":"Suppl 3","key":"10.3233\/JAD-150818_ref7","doi-asserted-by":"crossref","first-page":"III28","DOI":"10.1007\/PL00007823","article-title":"Drug-induced psychotic symptoms in Parkinson\u2019s disease. Problems, management and dilemma","volume":"248","author":"Kuzuhara","year":"2001","journal-title":"J Neurol"},{"key":"10.3233\/JAD-150818_ref8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0976-3147.143197","article-title":"Psychiatric aspects of Parkinson\u2019s disease","volume":"6","author":"Grover","year":"2015","journal-title":"J Neurosci Rural Pract"},{"key":"10.3233\/JAD-150818_ref9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2011.1360","article-title":"Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis","volume":"306","author":"Maher","year":"2011","journal-title":"JAMA"},{"key":"10.3233\/JAD-150818_ref10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: Number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.3233\/JAD-150818_ref11","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/archneurol.2010.35","article-title":"Serotonin 2A receptors and visual hallucinations in Parkinson\u2019s disease","volume":"67","author":"Ballanger","year":"2010","journal-title":"Arch Neurol"},{"key":"10.3233\/JAD-150818_ref12","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s11064-014-1293-3","article-title":"On the discovery and development of pimavanserin: Anovel drug candidate for Parkinson\u2019s psychosis","volume":"39","author":"Hacksell","year":"2014","journal-title":"Neurochem Res"},{"key":"10.3233\/JAD-150818_ref13","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson\u2019s disease psychosis","volume":"35","author":"Meltzer","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.3233\/JAD-150818_ref14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: A randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"key":"10.3233\/JAD-150818_ref17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1037\/1082-989X.8.3.243","article-title":"How meta-analysis increases statistical power","volume":"8","author":"Cohn","year":"2003","journal-title":"Psychol Methods"},{"key":"10.3233\/JAD-150818_ref18","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.3233\/JAD-150818_ref19","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3565(24)29327-7","article-title":"5-hydroxytryptamine2A receptor inverse agonists as antipsychotics","volume":"299","author":"Weiner","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.3233\/JAD-150818_ref20","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1081\/CLT-120028749","article-title":"A comparison of the pharmacokinetics of oral and sublingual cyproheptadine","volume":"42","author":"Gunja","year":"2004","journal-title":"J Toxicol Clin Toxicol"},{"key":"10.3233\/JAD-150818_ref21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s10517-014-2563-4","article-title":"Effect of 5-HT(2A) receptor antagonists on blood flow in the carotid vessels upon elevation of serotonin level","volume":"157","author":"Yakovlev","year":"2014","journal-title":"Bull Exp Biol Med"},{"key":"10.3233\/JAD-150818_ref22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0014-2999(97)00115-5","article-title":"Partial role of 5-HT2 and 5-HT3 receptors in the activity of antidepressants in the mouse forced swimming test","volume":"325","author":"Redrobe","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.3233\/JAD-150818_ref23","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1017\/S1461145713001417","article-title":"5-HT2A receptor antagonists for the treatment of neuroleptic-induced akathisia: A systematic review and meta-analysis","volume":"17","author":"Laoutidis","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.3233\/JAD-150818_ref24","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/art.24673","article-title":"Association between the use of serotonin receptor 2A-blocking antidepressants and joint disorders","volume":"61","author":"Kling","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.3233\/JAD-150818_ref25","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2174\/156802608784936700","article-title":"5-HT(2A) inverse-agonists for the treatment of insomnia","volume":"8","author":"Teegarden","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.3233\/JAD-150818_ref26","unstructured":"Andreasen N (1984) Scale for the Assessment of Positive symptoms (SAPS). University of Iowa, Iowa City, IA, USA."},{"key":"10.3233\/JAD-150818_ref27","first-page":"153","volume-title":"In Recent developments in Parkinson\u2019s disease","author":"Fahn","year":"1987"},{"key":"10.3233\/JAD-150818_ref28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.3233\/JAD-150818_ref29","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.3233\/JAD-150818_ref30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF02190411","article-title":"Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs","volume":"244","author":"Ikeguchi","year":"1995","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.3233\/JAD-150818_ref31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1479-8301.2012.00432.x","article-title":"Mirtazapine improves visual hallucinations in Parkinson\u2019s disease: A case report","volume":"13","author":"Tagai","year":"2013","journal-title":"Psychogeriatrics"},{"key":"10.3233\/JAD-150818_ref32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1055\/s-0034-1367014","article-title":"Reduction of parkinsonism and psychosis with mirtazapine: A case report","volume":"47","author":"Godschalx-Dekker","year":"2014","journal-title":"Pharmacopsychiatry"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-150818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:02:04Z","timestamp":1777370524000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-150818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,2]]},"references-count":30,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/jad-150818","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,2]]}}}